Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 6c; Offers FY22 Revenue Guidance
August 3, 2022 4:09 PM EDTAdaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $43.7 million versus the consensus estimate of $42.3 million.
GUIDANCE:
Adaptive Biotechnologies sees FY2022 revenue of $185-195 million, versus the consensus of... More
